The slowing of gastric motility may worsen gastro-oesophageal reflux disease (GORD) or contribute to constipation, both of which can indirectly lead to complications associated with bleeding
A New Indication for Semaglutide (Wegovy) The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either obesity or overweight
While medications like Topiramate and Semaglutide (Ozempic) offer powerful tools, the decision of whether and how to use them, especially in combination, is one that demands careful consideration, detailed information, and, most importantly, professional medical guidance
When Is the Best Time to Take Semaglutide
Schedule a consultation with a trusted bariatric surgeon in Los Angeles at Torrance Bariatrics today